Sanofi-Aventis has won its second bellwether verdict over its chemotherapy drug Taxotere.

A federal jury came back with a defense verdict late Thursday night after two weeks of trial in New Orleans. The trial is the second bellwether from among nearly 12,500 lawsuits coordinated in multidistrict litigation alleging that women who take Taxotere, which is used to treat breast cancer, never grow back their hair. The first bellwether trial ended in a defense verdict in 2019.

The jury found Sanofi-Aventis, which has U.S. headquarters in New Jersey, had not failed to warn of the side effect, which the U.S. Food and Drug Administration acknowledged in a labeling change in 2015.